Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(13.60) per share which missed the analyst consensus estimate of $(4.26) by 219.25 percent. This is a 97.67 percent increase over losses of $(584.45) per share from the same period last year. The company reported quarterly sales of $20.272 million which beat the analyst consensus estimate of $4.211 million by 381.41 percent. This is a 815.63 percent increase over sales of $2.214 million the same period last year.